{"id":48845,"date":"2025-11-24T15:42:19","date_gmt":"2025-11-24T07:42:19","guid":{"rendered":"https:\/\/flcube.com\/?p=48845"},"modified":"2025-11-24T15:42:19","modified_gmt":"2025-11-24T07:42:19","slug":"valo-health-partners-with-merck-on-3b-parkinsons-disease-discovery-deal","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=48845","title":{"rendered":"Valo Health Partners with Merck on $3B Parkinson&#8217;s Disease Discovery Deal"},"content":{"rendered":"\n<p><strong>Valo Health, Inc.<\/strong> announced a strategic collaboration with <strong>Merck KGaA<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/MRK:ETR\">ETR: MRK<\/a>) to advance therapeutic discovery in <strong>Parkinson&#8217;s disease and related disorders<\/strong>, leveraging Valo&#8217;s <strong>AI-enabled human causal biology platform<\/strong> and closed-loop chemistry capabilities. The partnership includes upfront and milestone payments totaling <strong>up to $3 billion<\/strong>, plus royalties and R&amp;D funding.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-deal-structure\">Deal Structure<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Partners<\/strong><\/td><td>Valo Health, Inc. &amp; Merck<\/td><\/tr><tr><td><strong>Focus Area<\/strong><\/td><td>Parkinson&#8217;s disease and related neurological disorders<\/td><\/tr><tr><td><strong>Deal Value<\/strong><\/td><td>Up to <strong>USD 3\u202fbillion<\/strong> in milestones, plus royalties and R&amp;D funding<\/td><\/tr><tr><td><strong>Valo&#8217;s Contribution<\/strong><\/td><td>AI platform with <strong>17\u202fmillion+ de-identified patient records<\/strong>, closed-loop discovery chemistry<\/td><\/tr><tr><td><strong>Merck&#8217;s Contribution<\/strong><\/td><td>Clinical development expertise, global scale, commercialization<\/td><\/tr><tr><td><strong>Strategic Goal<\/strong><\/td><td>Identify novel targets and rapidly generate preclinical compounds<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-technology-platform\">Technology Platform<\/h2>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-human-causal-biology-platform\">Human Causal Biology Platform<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Data Scale:<\/strong> Access to <strong>17\u202fmillion de-identified patient records<\/strong> spanning 20\u201130 years and biobank samples<\/li>\n\n\n\n<li><strong>AI Capability:<\/strong> Uncovers disease patterns and pinpoints novel therapeutic targets using advanced machine learning<\/li>\n\n\n\n<li><strong>Neurology Focus:<\/strong> Identifies distinct Parkinson&#8217;s phenotypes across disease spectrum with unique clinical characteristics<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-closed-loop-chemistry-platform\">Closed-Loop Chemistry Platform<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Function:<\/strong> Rapidly develops and optimizes small molecules engineered for human-validated targets<\/li>\n\n\n\n<li><strong>Speed:<\/strong> Accelerates preclinical candidate generation vs. traditional discovery methods<\/li>\n\n\n\n<li><strong>Integration:<\/strong> Seamlessly connects target validation to compound optimization<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-valo-s-dual-strategy\">Valo&#8217;s Dual Strategy<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Approach<\/th><th>Description<\/th><\/tr><\/thead><tbody><tr><td><strong>Proprietary Pipeline<\/strong><\/td><td>Advancing own assets across multiple disease areas<\/td><\/tr><tr><td><strong>Pharma Partnerships<\/strong><\/td><td>Collaborating with companies like Merck to accelerate R&amp;D and de-risk development<\/td><\/tr><tr><td><strong>Synergy<\/strong><\/td><td>Combines Valo&#8217;s early-stage capabilities with Merck&#8217;s late-stage expertise for faster patient delivery<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-impact-amp-outlook\">Market Impact &amp; Outlook<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Parkinson&#8217;s Market:<\/strong> Global Parkinson&#8217;s therapeutics market valued at <strong>$4.2\u202fbillion<\/strong> (2024), growing at <strong>6% CAGR<\/strong><\/li>\n\n\n\n<li><strong>Unmet Need:<\/strong> No disease-modifying therapies approved; current treatments only manage symptoms<\/li>\n\n\n\n<li><strong>Competitive Landscape:<\/strong> Valo-Merck partnership positions against <strong>Denali\/Sanofi<\/strong> and <strong>AstraZeneca\/Takeda<\/strong> alliances<\/li>\n\n\n\n<li><strong>Revenue Potential:<\/strong> If successful, Merck&#8217;s commercialization could generate <strong>peak sales of $2\u20113\u202fbillion<\/strong> for a breakthrough therapy<\/li>\n\n\n\n<li><strong>Valo Valuation:<\/strong> $3\u202fbillion deal validates Valo&#8217;s platform, potentially increasing its private valuation by <strong>40\u201160%<\/strong><\/li>\n<\/ul>\n\n\n\n<p><strong>Forward-Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding Valo&#8217;s collaboration with Merck, development timelines, and market potential. Actual results may differ materially due to risks including preclinical-to-clinical translation, competitive dynamics, and regulatory approvals.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Valo Health, Inc. announced a strategic collaboration with Merck KGaA (ETR: MRK) to advance therapeutic&#8230;<\/p>\n","protected":false},"author":1,"featured_media":48846,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[99,1147,120,3119],"class_list":["post-48845","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-deals","tag-ai","tag-etr-mrk","tag-merck","tag-valo-health"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Valo Health Partners with Merck on $3B Parkinson&#039;s Disease Discovery Deal - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Valo Health, Inc. announced a strategic collaboration with Merck KGaA (ETR: MRK) to advance therapeutic discovery in Parkinson&#039;s disease and related disorders, leveraging Valo&#039;s AI-enabled human causal biology platform and closed-loop chemistry capabilities. The partnership includes upfront and milestone payments totaling up to $3 billion, plus royalties and R&amp;D funding.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=48845\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Valo Health Partners with Merck on $3B Parkinson&#039;s Disease Discovery Deal\" \/>\n<meta property=\"og:description\" content=\"Valo Health, Inc. announced a strategic collaboration with Merck KGaA (ETR: MRK) to advance therapeutic discovery in Parkinson&#039;s disease and related disorders, leveraging Valo&#039;s AI-enabled human causal biology platform and closed-loop chemistry capabilities. The partnership includes upfront and milestone payments totaling up to $3 billion, plus royalties and R&amp;D funding.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=48845\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-11-24T07:42:19+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/2402.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=48845#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=48845\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Valo Health Partners with Merck on $3B Parkinson&#8217;s Disease Discovery Deal\",\"datePublished\":\"2025-11-24T07:42:19+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=48845\"},\"wordCount\":365,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=48845#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/2402.webp\",\"keywords\":[\"AI\",\"ETR: MRK\",\"Merck\",\"Valo Health\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=48845#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=48845\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=48845\",\"name\":\"Valo Health Partners with Merck on $3B Parkinson's Disease Discovery Deal - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=48845#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=48845#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/2402.webp\",\"datePublished\":\"2025-11-24T07:42:19+00:00\",\"description\":\"Valo Health, Inc. announced a strategic collaboration with Merck KGaA (ETR: MRK) to advance therapeutic discovery in Parkinson's disease and related disorders, leveraging Valo's AI-enabled human causal biology platform and closed-loop chemistry capabilities. The partnership includes upfront and milestone payments totaling up to $3 billion, plus royalties and R&D funding.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=48845#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=48845\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=48845#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/2402.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/2402.webp\",\"width\":1080,\"height\":608,\"caption\":\"Valo Health Partners with Merck on $3B Parkinson's Disease Discovery Deal\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=48845#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Valo Health Partners with Merck on $3B Parkinson&#8217;s Disease Discovery Deal\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Valo Health Partners with Merck on $3B Parkinson's Disease Discovery Deal - Insight, China&#039;s Pharmaceutical Industry","description":"Valo Health, Inc. announced a strategic collaboration with Merck KGaA (ETR: MRK) to advance therapeutic discovery in Parkinson's disease and related disorders, leveraging Valo's AI-enabled human causal biology platform and closed-loop chemistry capabilities. The partnership includes upfront and milestone payments totaling up to $3 billion, plus royalties and R&D funding.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=48845","og_locale":"en_US","og_type":"article","og_title":"Valo Health Partners with Merck on $3B Parkinson's Disease Discovery Deal","og_description":"Valo Health, Inc. announced a strategic collaboration with Merck KGaA (ETR: MRK) to advance therapeutic discovery in Parkinson's disease and related disorders, leveraging Valo's AI-enabled human causal biology platform and closed-loop chemistry capabilities. The partnership includes upfront and milestone payments totaling up to $3 billion, plus royalties and R&D funding.","og_url":"https:\/\/flcube.com\/?p=48845","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-11-24T07:42:19+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/2402.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=48845#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=48845"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Valo Health Partners with Merck on $3B Parkinson&#8217;s Disease Discovery Deal","datePublished":"2025-11-24T07:42:19+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=48845"},"wordCount":365,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=48845#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/2402.webp","keywords":["AI","ETR: MRK","Merck","Valo Health"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=48845#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=48845","url":"https:\/\/flcube.com\/?p=48845","name":"Valo Health Partners with Merck on $3B Parkinson's Disease Discovery Deal - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=48845#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=48845#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/2402.webp","datePublished":"2025-11-24T07:42:19+00:00","description":"Valo Health, Inc. announced a strategic collaboration with Merck KGaA (ETR: MRK) to advance therapeutic discovery in Parkinson's disease and related disorders, leveraging Valo's AI-enabled human causal biology platform and closed-loop chemistry capabilities. The partnership includes upfront and milestone payments totaling up to $3 billion, plus royalties and R&D funding.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=48845#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=48845"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=48845#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/2402.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/2402.webp","width":1080,"height":608,"caption":"Valo Health Partners with Merck on $3B Parkinson's Disease Discovery Deal"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=48845#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Valo Health Partners with Merck on $3B Parkinson&#8217;s Disease Discovery Deal"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/2402.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/48845","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=48845"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/48845\/revisions"}],"predecessor-version":[{"id":48847,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/48845\/revisions\/48847"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/48846"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=48845"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=48845"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=48845"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}